Shaun Rodriguez
Director/Board Member at Multiply Labs, Inc.
Profile
Shaun Rodriguez has worked as a Director at Multiply Labs, Inc. and Exai Bio, Inc.
Shaun Rodriguez active positions
| Companies | Position | Start |
|---|---|---|
Multiply Labs, Inc.
 Multiply Labs, Inc. Pharmaceuticals: MajorHealth Technology Multiply Labs, Inc. provides individuals to customize their intake of supplements to optimize their day. It offers vitamins, omega 3, iron, folic acid and caffeine medicines. The company was founded by Alice Melocchi, Tiffany Kuo, Fred Parietti and Joe Wilson and is headquartered in San Francisco, CA. | Director/Board Member | - |
Exai Bio, Inc.
 Exai Bio, Inc. Packaged SoftwareTechnology Services Exai Bio, Inc. is an American next-generation liquid biopsy company founded by Hani Goodarzi, Babak Alipanahi, and Patrick Arensdorf. The company's mission is to enable early detection, accurate diagnosis, personalized and targeted treatment, and ultimately cure of cancer. Exai Bio's proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest and most accurate diagnosis of cancer. Patrick Arensdorf has been the CEO since incorporation. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Multiply Labs, Inc.
Multiply Labs, Inc. Pharmaceuticals: MajorHealth Technology Multiply Labs, Inc. provides individuals to customize their intake of supplements to optimize their day. It offers vitamins, omega 3, iron, folic acid and caffeine medicines. The company was founded by Alice Melocchi, Tiffany Kuo, Fred Parietti and Joe Wilson and is headquartered in San Francisco, CA. | Health Technology |
Exai Bio, Inc.
Exai Bio, Inc. Packaged SoftwareTechnology Services Exai Bio, Inc. is an American next-generation liquid biopsy company founded by Hani Goodarzi, Babak Alipanahi, and Patrick Arensdorf. The company's mission is to enable early detection, accurate diagnosis, personalized and targeted treatment, and ultimately cure of cancer. Exai Bio's proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest and most accurate diagnosis of cancer. Patrick Arensdorf has been the CEO since incorporation. | Technology Services |
- Stock Market
- Insiders
- Shaun Rodriguez
